Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 6/20 | 0.53 |
| ▸ | CTSS | P25774 | 6/20 | 0.53 |
| ▸ | CTSB | P07858 | 5/20 | 0.53 |
| ▸ | CTSK | P43235 | 5/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1018180 | 0.92 | CTSL (0.57) | CTSLCTSSCTSBCTSKTACR1 | |
| SCHEMBL9900827 | 0.88 | CTSL (0.63) | CTSLCTSSCTSBCTSKTACR1 | |
| SCHEMBL62133 | 0.85 | CTSS (0.49) | CTSLCTSSCTSBCTSKTACR1 | |
| SCHEMBL2081142 | 0.83 | MEN1 (0.51) | CTSLCTSSCTSBCTSKPREP | |
| SCHEMBL52449 | 0.83 | CTSS (0.52) | CTSLCTSSCTSBCTSK | |
| SCHEMBL51465 | 0.83 | CTSL (0.49) | CTSLCTSSCTSBCTSKTACR1 | |
| SCHEMBL9942953 | 0.83 | CTSL (0.49) | CTSLCTSSCTSBCTSKTACR1 | |
| SCHEMBL87370 | 0.82 | CTSS (0.51) | CTSLCTSSCTSBCTSKPREP | |
| SCHEMBL52043 | 0.82 | CTSS (0.48) | CTSLCTSSCTSBCTSKPREP | |
| SCHEMBL606307 | 0.81 | CTSB (0.49) | CTSLCTSSCTSBCTSKTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515916-B1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11529347-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11529347-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPN21, PTPN22, PTPN5 | CTSL 3554/4885CTSS 3718/4885CTSB 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.